BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting

Plenary presentation of Phase 3 tislelizumab trial in first-line RM-NPC Primary analysis of zanubrutinib Phase 2 ROSEWOOD trial in follicular lymphoma Long-term data from zanubrutinib Phase 3

Related Keywords

Australia ,China ,Li Zhang ,Zhejiang ,Japan ,United States ,Canada ,United Kingdom ,America ,Great Britain ,American ,Kuaile Zhao ,Emmanuel Bachy ,Lai Wang ,Kyle Blankenship ,Kevin Mannix ,Jorgej Castillo ,Keun Wook Lee ,Julien Edeline ,Keun Seok Lee ,Jian Li ,Jia Fan ,Constantines Tam ,Eric Van Cutsem ,Amgen ,Drug Administration ,Novartis ,Exchange Commission ,China National Medical Products Administration ,European Union ,Bristol Myers Squibb ,American Society ,Cancer Oncology ,Global Head ,Gene Poster ,Oral Presentations ,Chronic Lymphocytic Leukemia ,Gastrointestinal Cancer Gastroesophageal ,Breast Cancer Metastatic ,Seok Lee ,Wook Lee ,Gene Online Only Abstracts ,Lii Cheng ,Van Cutsem ,Mirati Therapeutics ,North America ,Novartis Oncology ,Private Securities Litigation Reform Act ,Beigene ,Present ,Linical ,Data ,Rom ,Nnovative ,Ncology ,Portfolio ,022 ,Disco ,Nnual ,Meeting ,